TP53 and neoplasm: Unfortunately, the lack of R273H mutant tumors in this cohort preclude a comparison in this instance, but clinical data from TCGA Pan Cancer Atlas studies (cBioportal) provide evidence of survival disadvantage in patients with R273C p53 mutation compared to R273H (Supplementary Fig. 6C), albeit with some variation between tumor types.